ClinicalTrials.gg
CompletedNCT06339788Updated Feb 4, 2025

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

A Phase 1 interventional study of HD-P023 and Teneligliptin in Healthy Volunteers, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Handok Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are 19 years or older on screening
  • Signed
  • Healthy Volunteer
  • Other inclusion applies

Exclusion criteria

Exclusion Criteria:

  • /significant findings as evaluated by the investigator
  • Other exclusion applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    HD-P023

    One tablet of HD-P023 by oral

    Drug: HD-P023

  • Active comparator
    Co-administration of Teneligliptin and Empagliflozin High

    One tablet each of Teneligliptin and Empagliflozin High by oral

    Drug: Teneligliptin · Drug: Empagliflozin

Interventions

  • DrugHD-P023

    Single dose administration of HD-P023

  • Single does administration of Teneligliptin and Empagliflozin High

  • Single does administration of Teneligliptin and Empagliflozin High

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUCt) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

  2. Peak Plasma Concentration (Cmax) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

Secondary outcomes

  1. Area under the plasma concentration versus time curve zero to time infinity (AUC∞) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

  2. Ratio of AUCt and AUC∞ (AUCt/AUC∞) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

  3. Time to peak drug concentration (Tmax) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

  4. Volume of distribution (VZ/F) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

  5. Clearance (CL/F) of Teneligliptin and Empagliflozin

    Time frame: 72 hours

07

Study locations

1 site
  • Central Hospital
    Siheung-si, Gyeonggi-do, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jun 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 1, 2024
StartActual
May 10, 2024
Primary completionActual
Jun 12, 2024
CompletionActual
Jun 12, 2024
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06339788
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
May 10, 2024
Primary completion
Jun 12, 2024
Completion
Jun 12, 2024
Last update
Feb 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion